Transgene SA (FRA:TGNA)

Germany flag Germany · Delayed Price · Currency is EUR
0.854
-0.046 (-5.11%)
At close: Dec 4, 2025
21.31%
Market Cap 250.83M
Revenue (ttm) 7.58M
Net Income (ttm) -36.78M
Shares Out n/a
EPS (ttm) -0.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,111
Average Volume 1,496
Open 0.840
Previous Close 0.900
Day's Range 0.840 - 0.854
52-Week Range 0.550 - 1.485
Beta n/a
RSI 23.68
Earnings Date n/a

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1979
Employees 144
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol TGNA
Full Company Profile

Financial Performance

In 2024, Transgene's revenue was 6.35 million, a decrease of -19.58% compared to the previous year's 7.90 million. Losses were -33.97 million, 52.1% more than in 2023.

Financial Statements

News

There is no news available yet.